News and Trends 23 Dec 2022 Mersana Therapeutics and Merck to develop novel ADCs Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […] December 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Merck and Kelun-Biotech collaborating on seven ADC cancer candidates Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 2022 is coming to an end. Here is a list of biotech companies from around the world that we are keeping in our sights in 2023. The year 2022 has seen a lot of uncertainty in biotech markets, resulting in tumbling or volatile stocks. A high number of biotech companies are even trading with market […] December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic test from the Norwegian university hospital AHUS. The company said it will pursue cost-efficient product development with […] December 22, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 First CAR-T technology trial for patients with T-cell leukemia subtype authorized The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […] December 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Ganymede Bio raises $12.75M for data platform Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, has announced a $12.75 million series A funding round, led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to more than $15.6 million. Founded in 2022, Ganymede Bio has exceeded $1 million […] December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Positive Dupixent eosinophilic esophagitis phase 3 results The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […] December 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Japanese companies look to reduce environmental impact Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a collaboration to reduce the environmental impact of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentally-friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies […] December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Spanish foodtech grows in 2022 Eatable Adventures, an agrifood accelerator, has presented the data from its annual study “The State of Foodtech in Spain 2022.” The report gathers information on the characterization and investment evolution of the Spanish foodtech entrepreneurial ecosystem. The report says 2022 has been a positive year for the sector in the country. Despite the macroeconomic context, […] December 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Watch: Biocant Park – a biotech hub in the heart of Portugal Biocant Park is a science and technology park specializing in biotechnology, with a unique innovation environment among the sector in Portugal. Located in Cantanhede, between Porto and Lisbon, the park aims to promote, develop and apply advanced knowledge in life sciences. Currently, the park has four buildings with laboratories and offices for companies, and a […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2022 Watch: Aphaia Pharma interview Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email